Error: Microsoft.Office.Server.Search.Query.QueryMalformedException: Your query is malformed. Please rephrase your query. ---> System.ServiceModel.FaultException`1[Microsoft.Office.Server.Search.Administration.SearchServiceApplicationFault]: The creator of this fault did not specify a Reason. (Fault Detail is equal to Microsoft.Office.Server.Search.Administration.SearchServiceApplicationFault). --- End of inner exception stack trace --- at Microsoft.Office.Server.Search.Administration.SearchServiceApplicationProxy.ThrowBackwardCompatibleException(FaultException`1 ex) at Microsoft.Office.Server.Search.Administration.SearchServiceApplicationProxy.DoSpLoadBalancedUriWsOp[T](WebServiceBackedOperation`1 webServiceCall, Int32 timeoutInMilliseconds, Int32 wcfTimeoutInMilliseconds, String operationName) at Microsoft.Office.Server.Search.Administration.SearchServiceApplicationProxy.DoWebServiceBackedOperation[T](String operationName, Int32 timeoutInMilliseconds, Int32 wcfTimeoutInMilliseconds, WebServiceBackedOperation`1 webServiceCall) at Microsoft.Office.Server.Search.Administration.SearchServiceApplicationProxy.Execute(QueryProperties properties) at Microsoft.Office.Server.Search.Query.Query.Execute() at AVMA_Web_Parts.WebParts.RelatedBlogsAndNews.RelatedBlogsAndNews.<>c__DisplayClass2.b__0() at Microsoft.SharePoint.SPSecurity.<>c__DisplayClass4.b__2() at Microsoft.SharePoint.Utilities.SecurityContext.RunAsProcess(CodeToRunElevated secureCode) at Microsoft.SharePoint.SPSecurity.RunWithElevatedPrivileges(WaitCallback secureCode, Object param) at Microsoft.SharePoint.SPSecurity.RunWithElevatedPrivileges(CodeToRunElevated secureCode) at AVMA_Web_Parts.WebParts.RelatedBlogsAndNews.RelatedBlogsAndNews.CreateChildControls()

May 15, 2010

 

 FDA allows propofol imports to address short supply

posted May 1, 2010
 

The Food and Drug Administration is temporarily allowing APP Pharmaceuticals to import an unapproved propofol 1 percent product to help address a shortage of the anesthetic agent.

APP previously received FDA approval, late last year, to import and distribute Fresenius Propoven 1% after recalls of propofol injection by other U.S. manufacturers—Hospira and Teva Animal Health. The FDA reinstated permission for APP to import Fresenius Propoven 1% following continuing supply issues with other U.S. manufacturers.

APP's parent company, Fresenius Kabi of Germany, manufactures Fresenius Propoven 1% in FDA-compliant facilities.

APP, with FDA agreement, is temporarily introducing Fresenius Propoven 1% in a 20-mL glass ampule. Health care providers should use a 5 micron filter when withdrawing the product from the glass ampule. APP is shipping a Becton Dickinson 5 micron blunt filter needle with each 20-mL glass ampule of Fresenius Propoven 1%.

Fresenius Propoven 1% is also available in 20-mL, 50-mL, and 100-mL vials. APP will continue to offer its own brand-name propofol 1% product, Diprivan, and increase the supply of its generic product.

Additional information and a Q&A about the propofol shortage and Fresenius Propoven 1% are available from the FDA at www.fda.gov/Drugs/DrugSafety/DrugShortages by clicking on "Current Drug Shortages" and scrolling down to the propofol entry.

Health care providers may contact APP Customer Service by calling (888) 386-1300 or contact APP Medical Information by calling (800) 551-7176 or e-mailing appmedicalinfo@APPpharma.com.